Canada markets open in 4 hours 3 minutes

Cingulate Inc. (CING)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9607-0.0292 (-2.95%)
At close: 03:58PM EST
0.9600 -0.00 (-0.07%)
After hours: 05:06PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.9899
Open0.9800
Bid0.0000 x 1000
Ask0.0000 x 2200
Day's Range0.9600 - 1.0000
52 Week Range0.6640 - 2.2000
Volume11,956
Avg. Volume52,783
Market Cap10.865M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.1560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • GlobeNewswire

    Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

    Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco KANSAS CITY, Kan., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the initiation of the first Phase 3 clinic

  • GlobeNewswire

    Cingulate Benzinga All Live Access Appearance Rescheduled for December 16

    KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on Friday December 16, 2022, at 9:20 a.m. CST. The appearance had previously been scheduled for Friday

  • GlobeNewswire

    Cingulate to Participate in Benzinga All Live Access Event

    KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday December 2, 2022, at 10 a.m. CST. The discussion will address the current unmet needs in Attention De